Dear NSGO members,

At the time this year’s Annual Meeting was planned and Bergen or Helga Salvesen’s home town was selected as the host, it was only natural to choose translational research as the Main Theme. Then in January we received the sad news about Helga’s death, and the Meeting became her Memorial Meeting. However, I’m sure that Helga would have liked the Meeting, the scientific program of which was extraordinarily good, thanks to the excellent speakers we had. The two Satellite Symposia arranged in collaboration with AstraZeneca and Roche amended nicely the Translational Research Program of the Main Meeting. We thank Line Bjorge and her staff, as well as NSGO Office Staff for excellent arrangements during and before the meeting. The financial support by our Gold Sponsors or AstraZeneca, Roche, SOBI and Tesaro, and our Partner OvaCure, is highly appreciated; without this cooperation it would be very difficult to organize Annual Meetings.

The term of quite many Board Members ended at the Annual Meeting in Bergen. I thank all of them for their valuable contribution to the Society. Here I like to especially mention our Secretary or Maria Bjurberg, who was always very fast and punctual in her way of writing the Minutes; tack så mycket, Maria! Two ex-Board members have agreed to take extra tasks in the future: We appreciate that Caroline Lundgren has volunteered to become the chair of the upcoming Nominating Committee, which will be activated at the Annual Meeting 2017. I’m also very glad that the Surgery Group has finally been re-activated, thanks to Jan Blaakaer, who also has gathered a Working Group for modernizing the obsolete staging system for cervical cancer. Of course we cannot do it alone, but we can always make suggestions to ESGO and FIGO.

The authorities are all the time tightening the rules by which they regulate the support Pharma Industry can give to educational activities like our Annual Meetings. Consequently, we have to be prepared to accommodate our activities with decreasing external support. Because CTU takes care of trial activities, the Society has very limited means for income, apart from membership and registration fees. Against this background, it is very alarming that our members are not willing to pay their membership fees: only less than one third of our members pay their fee, while more than two thirds have chosen not to pay. I don’t really understand this situation, because the membership fee is so small that it simply cannot be a financial burden to any physician or physicist. I do hope that the reason is laziness only rather than lack of commitment, because a lack of commitment would pose a serious threat to the future of NSGO. We’ll discuss the problem at the Strategic Meeting of the Board in September, but at this point I urge our silent members to pay their membership fees. It is very easy to take care of, just go the Website and follow the Instructions.

Now it is time to thank Joseph Carlson for editing four previous Newsletters, and congratulate Gabriel Lindahl who had the courage to become the new Editor. This Newsletter is the first one being edited by him, with the help and guidance by Joe. Solveig continues her excellent work with the Website.

Last but not least, I like to thank CTU’s Medical Director or Mansoor Raza Mirza, whom endless activity I can only admire. NSGO is now the Sponsor of several trials, just to mention here AVANOVA and Umbrella. I let him tell more in his Column. Mansoor has now got a Deputy Medical Director or Trine Juhler Nottrup, to help him besides the excellent Office Staff of Louisa, Solveig, Kicki, Joan and Eva.

I wish you all a relaxing summer!

Johanna Mäenpää
President

Let’s all meet at the 30th Anniversary Meeting of NSGO on May 4-5th, 2017, in Helsinki!
Dear NSGO colleagues,

We have had a busy first half of 2016 and we are successfully moving further to initiate all the new trials in pipeline. Below are some headlines:

**Ovarian Cancer:**

**ENGOT-OV16/NOVA**

We had to withdraw our Late-Breaking-Abstract from ASCO, as the events for final PFS analysis were not reached.

Now the PFS is reached and the study results will be presented both at ESMO as well as at IGCS.

**ENGOT-OV24/AVANOVA**

The part 1 of the study is completed and results were presented at ASCO as a poster. Part 2 is already enrolling patients.

**NSGO-OVUMB1 (ENGOT-OV30):**

After discussions with AstraZeneca, some changes are made in this study proposal and new agents are being added in two of the study cohorts. We hope to finalize the protocol early fall to be activated by end of ‘16.

**Endometrial Cancer:**

**ENGOT-EN2-DGCCG**

The trial is accruing slowly (129 patients till date) and needs your attention and your help. We shall be opening sites in GEICO, Spain, MITO/MaNGO, Italy, CEGOG, Czech Republic, ISGO, Israel and NOGGO, Germany during 2016.

**ENGOT-EN1/FANDANGO**

The trial has been submitted to all NSGO countries and is already approved by some. Submissions are also completed in Germany and Belgium while France is Pending. We hope to start site initiation in September.

**ENGOT-EN3/PALEO**

This trial is submitted in Denmark, while submissions in other Nordic countries are under way. NOGGO, Germany, MITO, Italy and GEICO, Spain are participating in this study.

We had a successful Investigator meeting at Bergen Annual meeting and we are planning next investigator meeting at December 8 in Copenhagen.

NSGO-CTU was represented by Johanna and myself in the GCIG Ovarian Cancer. The publications will be available by end of the year.

Johanna & I also represented NSGO in endometrial cancer consensus. The publications from the ESMO-ESGO-ESTRO Endometrial Cancer Meeting are now available:

**ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.**


**ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.**


**ESMO-ESGO-ESTRO Consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.**


Thank you for your continuous support!

Best regards,

Mansoor
The Study Nurse Subcommittee
Chair: Louisa Boufercha, General Manager, NSGO

At the NSGO Annual Meeting 2016 in Bergen, a Study Nurse session was held for the NSGO Study Nurses. The study nurse session was held the 7th of April 2016 and had a duration of 2 hours, 5 study nurses attended the meeting.

During the session we had an introduction, an update of the Study Nurse working group, discussion of the future meeting structure and a presentation about RECIST.

Louisa Boufercha made a short introduction and gave an update on the NSGO Study Nurse working group that consists of: Åse Merete Thuen, Study Nurse (NO), Louisa Boufercha, General Manager (NSGO), Susanna Luukkonen, Study Nurse, (FI) and Janni Møldrup, Study Nurse (DK) who is a newly recruited member of the working group. Furthermore the future meeting structure for the Study Nurses was discussed and it was agreed that we will continue with two face-to-face meetings and two online meetings per year. In addition the newly updates from the Study Nurse website were shared. The Study Nurse Website has been created as a subsite to the NSGO website and is an opportunity for the Study Nurses to share documents, relevant information and to share better practices.

Following we had an external speaker, Sigmund Ytre-Hauge, MD, PhD-candidate from Haukeland University Hospital/University of Bergen who presented RECIST. Sigmund started with an introduction to RECIST and then presented the Assessment according to RECIST, Pitfalls and limitations; Alternative approaches and different cases were discussed. The session was successful, very informative and interactive.

As mentioned previously NSGO strongly encourage all Study Nurses to prioritize and to actively participate in the upcoming face-to-face meetings and online meetings. These meetings are an opportunity for the study nurses to strengthening their network and to share better practices. Furthermore it is important that all study nurses give input to the content and structure of the meetings including agendas in order to get a more valuable and positive outcome from the meetings. NSGO look forward to continue the collaboration with the NSGO Study Nurses in 2016.
From the NSGO Surgery Group  
Chair: Jan Blaakær, Aarhus

The NSGO department questionnaire has been mailed twice to the relevant contact persons.

The departments in Bergen, Copenhagen, Helsinki, Stockholm, Stavanger, and Tampere have completed the questionnaire.

The remaining departments are urgently invited to complete the questionnaire!

During the summertime the results from the questionnaire will be published on the NSGO website.

By visiting another Nordic gynecological oncologic center you might get good ideas for changing your working life and you may bring good ideas to the center you visit! By visiting each other in the NSGO member countries we also might facilitate the research environment between our centers and might open doors for our young colleagues and their expert education as claimed by the ESGO organization.

If you don’t have the questionnaire you can get it by sending me an email on the address: jab@dadlnet.dk and I will return the questionnaire to you!

Please notice that you don’t need to print it out, complete it and scan it again! You simply press the ‘Complete and sign’ in the right margin (in Danish: Udfyld og underskriv) – se below!

You can now complete the questionnaire on your computer, save it and mail it to me!

Kind regards

Jan.

<table>
<thead>
<tr>
<th>Hospital</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yearly number of patients diagnosed with</td>
<td>Number</td>
<td>Comment</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© Nordic Society of Gynaecological Oncology
WWW.NSGO.org | https://twitter.com/wwwNSGOorg
The NSGO Cervical Cancer Working Group

On April the 25th 2016 the NSGO Board accepted the minutes of their Constitutional Meeting and the new Cervical Cancer Working Group was born!

The reason for the working group is that during the Annual NSGO meeting in Bergen this year, we had a session concerning the staging of cervical cancer. In the Nordic countries we use lots of resources on MRI, PET-CT and CT, but the cervical cancer staging is still clinical – and moreover, you do not correct the stage if you later on discover that the clinical staging was wrong. The NSGO Board therefore decided to establish this working group to examine if the time has come to propose a change in our staging of cervical cancer.

At the moment, Henrik Roed, Copenhagen, Maarit Anttila, Kuopio, Elisabeth Ávall-Lundqvist and Gabriel Lindahl, Linköping, Ingrid Helene Salvesen Haldorsen and Kathrine Woie, Bergen and Päivi Pakarinen, Helsinki and Jan Blaakær, Aarhus have been recruited for the working group. At the moment, I await a reply from the Icelandic members for the two members of the working group.

As soon as all members have been selected, we will arrange the first meeting. This meeting will be held after the summer break and I will inform you in the newsletter about the progress in the working group.

Have a nice summer!
Jan Blaakær, Aarhus.

A Final Word from the (new) Editor.

Dear colleagues,

After a successful annual meeting in Bergen (please see enclosed photos) with highly appreciated international speakers we immediately started the work preparing for the next meeting in Helsinki the 4:th and 5:th of May 2017 celebrating our 30:th anniversary. Parallel with this we keep up the continuous and important work of the board under the supervision of Johanna and of our trial unit under the management of Mansoor.

As we all know the Scandinavian summer is short, often unpredictable, but long-awaited. So let’s all enjoy our precious weeks of vacation before we head back to our offices to engage in our patients with new spirit and commitment.

And as I do the final editing of this issue, I’ve just witnessed the second Brexit in a week as Iceland miraculously beats England in Euro 2016. Maybe the lesson to be learned from all this is that collaboration is almost always to be preferred before individualism. And our organization is an excellent example of the former.

Let’s keep our fingers crossed and wish the Icelandic team the best of luck as they progress in the tournament!

Gabriel Lindahl, Linköping.

Save the Date

Investigator Meeting 8 December 2016, Copenhagen, Denmark
Annual Meeting 4-5 May 2017, Helsinki, Finland

NSGO GOLD SPONSORS 2016

AstraZeneca Roche Sobi Tesaro
NSGO Annual Meeting in Bergen 2016 in pictures...